Idiopathic pulmonary fibrosis: From epithelial injury to biomarkers-insights from the bench side

Respiration

Volumn 86, Issue 6, 2014, Pages 441-452

  Borensztajn, Keren ^a,b   Crestani, Bruno ^a,b   Kolb, Martin ^c  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Firestone Institute for Respiratory Health   (Canada)

Author keywords

Biomarkers; Epithelial injury; Fibrosis; Idiopathic pulmonary fibrosis; KL 6; Parenchymal lung disease; Surfactant proteins

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; INTERSTITIAL COLLAGENASE; KREBS VON DEN LUNGEN 6 ANTIGEN; LIPOPROTEIN; LIPOPROTEIN SP A; LIPOPROTEIN SP D; MATRILYSIN; OSTEOPONTIN; UNCLASSIFIED DRUG; VASCULOTROPIN; SP A LIPOPROTEIN COMPLEX; SP D LIPOPROTEIN COMPLEX;

CELL DAMAGE; CELLS; CIRCULATING FIBROCYTE; DISEASE ACTIVITY; FIBROSING ALVEOLITIS; HOMEOSTASIS; HUMAN; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM INJURY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; BONE MARROW DERIVED MESENCHYMAL STEM CELL; LUNG ALVEOLUS EPITHELIUM CELL; TISSUE REPAIR;

BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; EPITHELIAL CELLS; EPITHELIUM; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATION; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 7; MUCIN-1; OSTEOPONTIN; PULMONARY ALVEOLI; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893681263     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000357598     Document Type: Review

References (108)

1. King TE Jr, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
2. Carter NJ: Pirfenidone: in idiopathic pulmonary fibrosis. Drugs 2011; 71:1721-1732.
3. Poletti V, Ravaglia C, Buccioli M, Tantalocco P, Piciucchi S, Dubini A, Carloni A, Chilosi M, Tomassetti S: Idiopathic pulmonary fibro-sis: diagnosis and prognostic evaluation. Respiration 2013; 86:5-12.
4. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646-664.
5. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richel-di L, Selman M, Dudden RF, Griss BS, Protz-ko SL, Schunemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibro-sis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
6. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors June, 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
7. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D, ATS/ERS Committee on Idiopathic Interstitial Pneumonias: An official American Thoracic Society/European Respiratory Society statement: update of the international multidisci-plinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733-748.
8. van den Blink B, Wijsenbeek MS, Hoogsteden HC: Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2010; 23: 515-520.
9. Ley B, Collard HR, King TE Jr: Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:431-440.
10. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, To-massetti S, Lee JS, Poletti V, Buccioli M, Elick-er BM, Jones KD, King TE Jr, Collard HR: A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156:684-691.
11. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ: Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-1977.
12. Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151. (Pubitemid 32096342)
13. Kasper M, Haroske G: Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol 1996; 11: 463-483. (Pubitemid 26135211)
14. Katzenstein AL: Pathogenesis of 'fibrosis' in interstitial pneumonia: an electron microscopic study. Hum Pathol 1985; 16:1015-1024.
15. Kawanami O, Ferrans VJ, Crystal RG: Structure of alveolar epithelial cells in patients with fibrotic lung disorders. Lab Invest 1982; 46: 39-53. (Pubitemid 12167015)
16. Adamson IY, Bowden DH: Bleomycin-in-duced injury and metaplasia of alveolar type 2 cells. Relationship of cellular responses to drug presence in the lung. Am J Pathol 1979; 96:531-544. (Pubitemid 9253492)
17. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, Kaneko Y, Hara N: Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997; 17: 272-278. (Pubitemid 127500830)
18. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD: Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by cap-topril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000; 279:L143-L151. (Pubitemid 30619534)
19. Morishima Y, Nomura A, Uchida Y, Noguchi Y, Sakamoto T, Ishii Y, Goto Y, Masuyama K, Zhang MJ, Hirano K, Mochizuki M, Ohtsuka M, Sekizawa K: Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol Biol 2001; 24:1-11. (Pubitemid 32097502)
20. Marchand-Adam S, Plantier L, Bernuau D, Legrand A, Cohen M, Marchal J, Soler P, Leseche G, Mal H, Aubier M, Dehoux M, Crestani B: Keratinocyte growth factor expression by fibroblasts in pulmonary fibrosis: poor response to interleukin-1beta. Am J Respir Cell Mol Biol 2005; 32:470-477. (Pubitemid 40629333)
21. Marchand-Adam S, Fabre A, Mailleux AA, Marchal J, Quesnel C, Kataoka H, Aubier M, Dehoux M, Soler P, Crestani B: Defect of pro-hepatocyte growth factor activation by fibro-blasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:58-66. (Pubitemid 43955245)
22. Atabai K, Ishigaki M, Geiser T, Ueki I, Mat-thay MA, Ware LB: Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms. Am J Physiol Lung Cell Mol Physiol 2002; 283:L163-L169. (Pubitemid 34764553)
23. Dohi M, Hasegawa T, Yamamoto K, Marshall BC: Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000; 162:2302-2307. (Pubitemid 32051704)
24. Kim HJ, Sammak PJ, Ingbar DH: Hepatocyte growth factor stimulates migration of type II alveolar epithelial cells on the provisional matrix proteins fibronectin and fibrinogen. Chest 1999; 116:94S-95S. (Pubitemid 29340232)
25. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engel-hardt JF, Liu X, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH: Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181:254-263.
26. Plantier L, Crestani B, Wert SE, Dehoux M, Zweytick B, Guenther A, Whitsett JA: Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. Thorax 2011; 66:651-657.
27. Beers MF, Morrisey EE: The three R's of lung health and disease: repair, remodeling, and regeneration. J Clin Invest 2011; 121:2065-2073.
28. Bhattacharya J, Matthay MA: Regulation and repair of the alveolar-capillary barrier in acute lung injury. Annu Rev Physiol 2013; 75:593-615.
29. Fehrenbach H: Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2001; 2:33-46. (Pubitemid 34187905)
30. Matthay MA: Function of the alveolar epithelial barrier under pathologic conditions. Chest 1994; 105:67S-74S.
31. Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, Randell SH, Noble PW, Hogan BL: Type 2 alveolar cells are stem cells in adult lung. J Clin Invest 2013; 123: 3025-3036.
32. Adamson IY, Bowden DH: Derivation of type 1 epithelium from type 2 cells in the developing rat lung. Lab Invest 1975; 32:736-745.
33. Serrano-Mollar A, Nacher M, Gay-Jordi G, Closa D, Xaubet A, Bulbena O: Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2007; 176:1261-1268. (Pubitemid 350256480)
34. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK: Adult-onset pulmonary fi-brosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104:7552-7557. (Pubitemid 47185944)
35. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, Phillips JA 3rd, Lansdorp PM, Loyd JE, Armanios MY: Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105:13051-13056.
36. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, Rosenblatt RL, Girod CE, Garrity ER, Xing C, Garcia CK: Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PloS One 2010; 5:e10680.
37. Jin HL, Dong JC: Pathogenesis of idiopathic pulmonary fibrosis: from initial apoptosis of epithelial cells to lung remodeling? Chin Med J (Engl) 2011; 124:4330-4338.
38. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA: Alveolar epithelial cell mesen-chymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103:13180-13185. (Pubitemid 44338936)
39. 1 integrin links β-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 2009; 119:213-224.
40. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W, Sherrill TP, Plieth D, Neil-son EG, Blackwell TS, Lawson WE: Contribution of epithelial-derived fibroblasts to bleo-mycin-induced lung fibrosis. Am J Respir Crit Care Med 2009; 180:657-665.
41. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, Noble PW, Hogan BL: Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 2011; 108:E1475-E1483.
42. Moore BB, Peters-Golden M, Christensen PJ, Lama V, Kuziel WA, Paine R 3rd, Toews GB: Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2. Am J Physiol Lung Cell Mol Physiol 2003; 284:L342-L349. (Pubitemid 36164369)
43. Lama V, Moore BB, Christensen P, Toews GB, Peters-Golden M: Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygen-ase-2-dependent. Am J Respir Cell Mol Biol 2002; 27:752-758. (Pubitemid 35381185)
44. Bozyk PD, Moore BB: Prostaglandin E2 and the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 45:445-452.
45. Maher TM, Evans IC, Bottoms SE, Mercer PF, Thorley AJ, Nicholson AG, Laurent GJ, Tetley TD, Chambers RC, McAnulty RJ: Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182:73-82.
46. Mercer PF, Johns RH, Scotton CJ, Krupiczojc MA, Konigshoff M, Howell DC, McAnulty RJ, Das A, Thorley AJ, Tetley TD, Eickelberg O, Chambers RC: Pulmonary epithelium is a prominent source of proteinase-activated re-ceptor-1-inducible CCL2 in pulmonary fibro-sis. Am J Respir Crit Care Med 2009; 179:414-425.
47. Scotton CJ, Krupiczojc MA, Konigshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Maher TM, Nicholson AG, Moffatt JD, Laurent GJ, Derian CK, Eickelberg O, Chambers RC: Increased local expression of coagulation factor X contributes to the fibrot-ic response in human and murine lung injury. J Clin Invest 2009; 119:2550-2563.
48. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114:438-446. (Pubitemid 39071616)
49. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O'Byrne PM, Strieter RM, Kolb M: Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:588-594.
50. Gunther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P: Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 152-160.
51. Fung ET, Wright GL Jr, Dalmasso EA: Pro-teomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2000; 2:643-650. (Pubitemid 32057560)
52. Sackett DL, Haynes RB: The architecture of diagnostic research. BMJ 2002; 324:539-541.
53. Biomarkers Definitions Working Group: Bio-markers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
54. Doyle TJ, Pinto-Plata V, Morse D, Celli BR, Rosas IO: The expanding role of biomarkers in the assessment of smoking-related paren-chymal lung diseases. Chest 2012; 142:1027-1034.
55. Vij R, Noth I: Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012; 159:218-227.
56. Bandoh S, Fujita J, Ohtsuki Y, Ueda Y, Hojo S, Tokuda M, Dobashi H, Kurata N, Yoshi-nouchi T, Kohno N, Takahara J: Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyosi-tis/dermatomyositis. Ann Rheum Dis 2000; 59:257-262. (Pubitemid 30305566)
57. Ishii H, Mukae H, Kadota J, Kaida H, Nagata T, Abe K, Matsukura S, Kohno S: High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with nonspecific interstitial pneumonia. Thorax 2003; 58:52-57. (Pubitemid 36135359)
58. Ohshimo S, Yokoyama A, Hattori N, Ishika-wa N, Hirasawa Y, Kohno N: KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun 2005; 338:1845-1852. (Pubitemid 41643100)
59. Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, Silver RM: Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009; 36:773-780.
60. Ichiyasu H, Ichikado K, Yamashita A, Iyona-ga K, Sakamoto O, Suga M, Kohrogi H: Pneu-mocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia. Respiration 2012; 83: 190-197.
61. Snijdewint FG, von Mensdorff-Pouilly S, Ka-runtu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P: Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001; 93: 97-106. (Pubitemid 32539508)
62. Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N: Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998; 55: 307-319. (Pubitemid 28279672)
63. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M: Natural autoanti-body to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161:589-594. (Pubitemid 30129471)
64. Inoue Y, Nishimura K, Shiode M, Akutsu H, Hamada H, Fujioka S, Fujino S, Yokoyama A, Kohno N, Hiwada K: Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Tuber Lung Dis 1995; 76:230-233.
65. Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, Hirasawa Y, Hiwada K: Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibro-sis. Am J Respir Crit Care Med 1998; 158: 1680-1684.
66. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M: Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006; 260:429-434. (Pubitemid 44571130)
67. Goerke J: Pulmonary surfactant: functions and molecular composition. Biochim Bio-phys Acta 1998; 1408:79-89. (Pubitemid 28517859)
68. Cheng IW, Ware LB, Greene KE, Nuckton TJ, Eisner MD, Matthay MA: Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med 2003; 31:20-27. (Pubitemid 36151144)
69. Lawson WE, Crossno PF, Polosukhin VV, Roldan J, Cheng DS, Lane KB, Blackwell TR, Xu C, Markin C, Ware LB, Miller GG, Loyd JE, Blackwell TS: Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294:L1119-L1126.
70. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, DiMaio JM, Kinch LN, Grishin NV, Garcia CK: Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009; 84:52-59.
71. Zhang X, Jiang J, Chen WJ, Su LX, Xie LX: Genetic characterization of a Chinese family with familial idiopathic pulmonary fibrosis. Chin Med J (Engl) 2012; 125:1945-1951.
72. Greene KE, King TE Jr, Kuroki Y, Bucher-Bar-telson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ: Serum surfactant proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19: 439-446. (Pubitemid 34256957)
73. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, Shiratori M, Kuroki Y, Abe S: Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000; 162:1109-1114.
74. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE Jr: Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fi-brosis. Chest 2009; 135:1557-1563.
75. Hanumegowda C, Farkas L, Kolb M: Angio-genesis in pulmonary fibrosis: too much or not enough? Chest 2012; 142:200-207.
76. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, Nukiwa T: Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169:1203-1208. (Pubitemid 38680397)
77. Farkas L, Farkas D, Ask K, Moller A, Gauldie J, Margetts P, Inman M, Kolb M: VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009; 119:1298-1311.
78. Ando M, Miyazaki E, Ito T, Hiroshige S, Nu-reki SI, Ueno T, Takenaka R, Fukami T, Ku-mamoto T: Significance of serum vascular en-dothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung 2010; 188:247-252.
79. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF: Peripheral blood proteins predict mortality in idiopathic pulmonary fi-brosis. Am J Respir Crit Care Med 2012; 185: 67-76.
80. Smadja DM, Mauge L, Nunes H, d'Audigier C, Juvin K, Borie R, Carton Z, Bertil S, Blanchard A, Crestani B, Valeyre D, Gaussem P, Israel-Biet D: Imbalance of circulating en-dothelial cells and progenitors in idiopathic pulmonary fibrosis. Angiogenesis 2013; 16: 147-157.
81. Oikonomidi S, Kostikas K, Tsilioni I, Tanou K, Gourgoulianis KI, Kiropoulos TS: Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr Med Chem 2009; 16:1214-1228.
82. Fujishima S, Shiomi T, Yamashita S, Yogo Y, Nakano Y, Inoue T, Nakamura M, Tasaka S, Hasegawa N, Aikawa N, Ishizaka A, Okada Y: Production and activation of matrix me-talloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibro-sis. Arch Pathol Lab Med 2010; 134:1136-1142.
83. Zuo F, Kaminski N, Eugui E, Allard J, Yakhi-ni Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, Sheppard D, Pardo A, Selman M, Heller RA: Gene expression analysis reveals matrilysin as a key regulator of pulmonary fi-brosis in mice and humans. Proc Natl Acad Sci USA 2002; 99:6292-6297. (Pubitemid 34493305)
84. Vuorinen K, Myllarniemi M, Lammi L, Piirila P, Rytila P, Salmenkivi K, Kinnula VL: Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases. APMIS 2007; 115:969-975. (Pubitemid 47256289)
85. Checa M, Ruiz V, Montano M, Velazquez-Cruz R, Selman M, Pardo A: MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 2008; 124:465-472.
86. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, Sciurba F, Dauber J, Selman M, Gochuico BR, Kaminski N: MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fi-brosis. PLoS Med 2008; 5:e93.
87. O'Regan A: The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003; 14: 479-488. (Pubitemid 37296021)
88. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, Kaminski N: Up-regulation and profibrotic role of osteopontin in human id-iopathic pulmonary fibrosis. PLoS Med 2005; 2:e251.
89. Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M, Kon S, Uede T, Fuku-chi Y: Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2001; 24:264-271. (Pubitemid 32228374)
90. Kadota J, Mizunoe S, Mito K, Mukae H, Yo-shioka S, Kawakami K, Koguchi Y, Fukushi-ma K, Kon S, Kohno S, Saito A, Uede T, Nasu M: High plasma concentrations of osteopon-tin in patients with interstitial pneumonia. Respir Med 2005; 99:111-117. (Pubitemid 40017394)
91. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM: Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007; 353:104-108. (Pubitemid 44958347)
92. Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A, Wester-gren-Thorsson G, Selman M: Fibrocytes are a potential source of lung fibroblasts in idio-pathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40:2129-2140.
93. Mehrad B, Burdick MD, Strieter RM: Fibro-cyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009; 41:1708-1718.
94. Borie R, Quesnel C, Phin S, Debray MP, Marchal-Somme J, Tiev K, Bonay M, Fabre A, Soler P, Dehoux M, Crestani B: Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis. PloS One 2013; 8:e53736.
95. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, Kambouchner M, Valeyre D, Cres-tani B, Soler P: Dendritic cells accumulate in human fibrotic interstitial lung disease. Am J Respir Crit Care Med 2007; 176:1007-1014. (Pubitemid 350127845)
96. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, Valeyre D, Soumelis V, Crestani B, Soler P: Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006; 176:5735-5739.
97. Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, Feingold E, Juan-Guardela BM, Richards TJ, Lussier Y, Huang Y, Vij R, Lindell KO, Xue J, Gibson KF, Shapiro SD, Garcia JG, Kaminski N: Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5: 205ra136.
98. Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, Barrientos L, Mailleux A, Cigna N, Tubach F, Marchal-Somme J, Soler P, Chollet-Martin S, Cres-tani B: Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:759-766.
99. Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, Bon J, Soejima M, Levesque MC, Lindell KO, Gibson KF, Ka-minski N, Banga G, Oddis CV, Pilewski JM, Sciurba FC, Donahoe M, Zhang Y, Duncan SR: Patients with idiopathic pulmonary fi-brosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187:768-775.
100. Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csiz-madia E, Otterbein L, Soejima M, Levesque MC, Gibson KF, Kaminski N, Pilewski JM, Donahoe M, Sciurba FC, Duncan SR: Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibro-sis patients. J Immunol 2013; 191:2089-2095.
101. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, Valentine VG, Lindsay EK, George MP, Steele C, Duncan SR: CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PloS One 2010; 5:e8959.
102. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, Fry CD, White ES, Sis-son TH, Tayob N, Carnemolla B, Orecchia P, Flaherty KR, Hershenson MB, Murray S, Martinez FJ, Moore BB: Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303:L1046-L1056.
103. Okamoto M, Hoshino T, Kitasato Y, Saka-zaki Y, Kawayama T, Fujimoto K, Ohshima K, Shiraishi H, Uchida M, Ono J, Ohta S, Kato S, Izuhara K, Aizawa H: Periostin, a matrix protein, is a novel biomarker for id-iopathic interstitial pneumonias. Eur Respir J 2011; 37:1119-1127.
104. Sin DD, Vestbo J: Biomarkers in chronic obstructive pulmonary disease. Proc Am Tho-rac Soc 2009; 6:543-545.
105. Daniels CE, Jett JR: Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005; 11:431-437. (Pubitemid 41291088)
106. Vancheri C: Common pathways in idiopath-ic pulmonary fibrosis and cancer. Eur Respir Rev 2013; 22:265-272.
107. Huang HB, Peng XN, Nakajima J: Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan. Biosci Trends 2013; 7:172-177.
108. Maher TM: PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 2013; 22:148-152.